Expansion Therapeutics is a drug discovery and development firm which is trying to come up with cures for a number of genetic disorders. One of these is called myotonic dystrophy type I, which leads to adults developing muscular dystrophy. The had a Series A financing round which did very well, resulting in this company raising $55.3 million. There were four main firms which invested in Expansion Therapeutics in this round of financing. These were 5AM Ventures, Novartis Venture Fund, Sanofi Ventures, and Kleiner Perkins. Two other companies also participated which were RA Capital Management and Alexandria Venture Investments.
It is believed by those in the medical community that muscular dystrophy occurs when RNA hit toxic levels. Once this happens muscles, heart and various systems become defective. It is a hereditary disease and each generation has worse and worse symptoms. So far no one has come up with a treatment for muscular dystrophy which Expansion Therapeutics is trying to change.
The research that Expansion Therapeutics is using to develop an effective treatment for muscular dystrophy comes from Matthew D. Disney, Ph.D.’s lab. He is also the main scientific researcher for this company. He says he has been working on developing a treatment for this disease for the past 12 years and he believes they will come up with an effective treatment regimen. The first patients who will take this company’s medicines are those who have run out of any other option.
5Am Ventures, one of the main investors in Expansion Therapeutics, is led by Scott Rocklage, Ph.D. He first became involved with this company in 2003 as a venture partner and he was elevated to the role of managing partner a year later. He has a wealth of experience in the biotech industry. He started out as a researcher and over time transitioned to executive roles for a couple of different companies. He says he focuses 5AM Ventures on biotech startups like Expansion Therapeutics. His investment firm also uses their experience to help the companies they invest in by guiding them and their research, oftentimes on these companies board. Learn more: https://www.dialdish.com/scott-rocklage-seeks-to-conquer-cancer-by-targeting-mutant-rna-molecules/
Mikhail Blagoslonny is a professor at the Roswell Park Cancer Institute. Here he carries out extensive research on cancer and aging which are critical areas of study in the modern world. The scientist, who resides in New York is also oncology professor at the same institution. Blagosklonny is a talented scientist who has a rich educational background.
He studied internal medicine and enrolled for a doctorate because of his desire to excel in the field of research. He studied cardiology and medicine, fields which are essential for its area of interest.
After doing a doctorate, he got an appointment at the New York Medical College where he started serving as an associate professor in the field of medicine. He served the college until in 2002 when he went to Ordway, which is a research institute. Here, he held a position of senior scientist and continued to gain experience which led him to get a position as an oncology professor at Roswell Park Cancer Institute. The institution is well-known for working with scientists to discover ways of helping cancer patients. Through their extensive research, they have found some ways of helping cancer patients. Visit ResearchGate to keep up to date with Mikhail’s latest work.
The institution has every belief that Mikhail Blagosklonny has all it takes to help it in teaching students who are passionate about oncology. Through this position, Mikhail Blogosklonny has worked with other researchers and students. Mikhail is always ready to work with others and help students understand the field so as to become future scientists. At the institution, Mikhail has played a significant role in making a breakthrough on cancer and aging. His primary focus is cancer therapies and protection of healthy cells. He is also focused on the mechanism that underly aging.
Mikhail is also known for the formulation of the hypothesis on TOR as a signal for aging. The theory claims that TOR signaling is a key factor in cancer and aging. If the theory is correct, then drug such as rapamycin could be helpful in the treatment of cancer and extension of life. The scientist also carries out other endeavors such as editing. He works with Aging, Cell Cycle nd Oncotarget journals where he has significant contributions. Follow Mikhail on Google Scholar